Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: INC B007839; INCB 7839

Latest Information Update: 19 Oct 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Class Amides; Antineoplastics; Cyclopropanes; Esters; Piperazines; Piperidines; Small molecules; Spiro compounds
  • Mechanism of Action ADAM10 protein inhibitors; Tumour necrosis factor-alpha convertase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 07 Jun 2010 Efficacy and adverse events data from a phase I/II trial in Breast cancer presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
  • 13 Dec 2009 Efficacy, adverse events, pharmacocynamics and pharmacokinetics data from a phase I/II trial in breast cancer presented at the 32nd San Antonio Breast Cancer Symposium (SABCS-2009) ,
  • 26 Feb 2008 Phase-II clinical trials in Breast cancer (monotherapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top